Health Care & Life Sciences » Pharmaceuticals | Kyowa Hakko Kirin Co. Ltd.

Kyowa Hakko Kirin Co. Ltd. | Balance Sheet

Fiscal year is January-December. All values JPY Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
23,323
20,718
13,265
13,076
14,685
15,867
Total Accounts Receivable
208,105
150,112
210,393
218,385
244,125
285,743
Inventories
75,699
91,283
84,804
76,278
71,222
77,221
Other Current Assets
22,193
21,079
15,971
7,260
18,118
7,013
Total Current Assets
329,320
283,192
324,433
314,999
348,150
385,844
Net Property, Plant & Equipment
137,919
151,891
147,043
118,192
109,578
103,153
Total Investments and Advances
24,547
22,730
13,988
2,945
1,857
8,887
Intangible Assets
212,073
241,551
212,807
205,218
200,436
198,295
Other Assets
11,505
11,696
12,138
19,720
25,417
24,261
Total Assets
719,257
719,135
720,764
683,801
708,295
741,982
ST Debt & Current Portion LT Debt
6,345
5,033
5,047
5,830
1,588
Accounts Payable
22,589
22,729
19,086
18,230
16,364
Income Tax Payable
10,802
7,718
11,831
7,531
6,425
Other Current Liabilities
45,340
49,702
48,859
56,481
54,032
Total Current Liabilities
85,076
85,182
84,823
88,072
78,409
Long-Term Debt
292
355
471
1,170
1,227
Provision for Risks & Charges
23,360
7,435
5,604
6,552
4,226
Deferred Taxes
7,914
8,160
1,737
21,759
22,664
Other Liabilities
3,307
4,560
2,916
10,004
8,214
Total Liabilities
123,842
113,767
105,906
106,766
92,268
Common Equity (Total)
594,265
605,368
614,858
577,036
616,028
Total Shareholders' Equity
594,265
605,368
614,858
577,036
616,028
Total Equity
595,415
605,368
614,858
577,036
616,028
Liabilities & Shareholders' Equity
719,257
719,135
720,764
683,802
708,296
Accumulated Minority Interest
1,150
-
-
-
-

About Kyowa Hakko Kirin Co.

View Profile
Address
Otemachi Financial City Grand Cube
Tokyo Tokyo 100
Japan
Employees -
Website http://www.kyowa-kirin.co.jp
Updated 07/08/2019
Kyowa Hakko Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It operates through the Pharmaceuticals and Bio-Chemicals segments. The Pharmaceuticals segment deals with the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension.